State of Wyoming Has $145,000 Stock Position in Cencora, Inc. (NYSE:COR)

State of Wyoming trimmed its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 71.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 644 shares of the company's stock after selling 1,575 shares during the period. State of Wyoming's holdings in Cencora were worth $145,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in COR. JFS Wealth Advisors LLC raised its holdings in shares of Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after purchasing an additional 46 shares during the period. Banque Transatlantique SA purchased a new stake in shares of Cencora during the 4th quarter valued at about $29,000. SBI Securities Co. Ltd. purchased a new stake in shares of Cencora during the 4th quarter valued at about $30,000. Kentucky Trust Co purchased a new stake in shares of Cencora during the 4th quarter valued at about $33,000. Finally, WASHINGTON TRUST Co raised its holdings in shares of Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after buying an additional 46 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Cencora

In other Cencora news, Chairman Steven H. Collis sold 14,579 shares of the business's stock in a transaction dated Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total value of $4,108,507.99. Following the completion of the sale, the chairman now owns 315,913 shares of the company's stock, valued at $89,027,442.53. The trade was a 4.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Robert P. Mauch sold 4,970 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $255.00, for a total value of $1,267,350.00. Following the transaction, the chief executive officer now directly owns 51,070 shares of the company's stock, valued at $13,022,850. This represents a 8.87% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 45,223 shares of company stock worth $12,369,767 over the last 90 days. 10.80% of the stock is currently owned by corporate insiders.

Cencora Stock Up 0.4%

Shares of COR stock traded up $1.08 on Thursday, reaching $290.27. 919,363 shares of the company's stock traded hands, compared to its average volume of 1,540,909. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $309.35. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The company has a market capitalization of $56.26 billion, a P/E ratio of 41.29, a price-to-earnings-growth ratio of 1.31 and a beta of 0.60. The business's 50 day moving average price is $283.90 and its two-hundred day moving average price is $257.97.

Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The firm had revenue of $75.50 billion for the quarter, compared to the consensus estimate of $75.41 billion. During the same quarter in the previous year, the company posted $3.80 earnings per share. The business's quarterly revenue was up 10.3% compared to the same quarter last year. On average, equities analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 2nd. Shareholders of record on Friday, May 16th will be paid a $0.55 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a yield of 0.76%. Cencora's dividend payout ratio (DPR) is currently 25.52%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on COR. Citigroup raised their price objective on Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Wells Fargo & Company boosted their price objective on Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research report on Friday, March 14th. Wall Street Zen upgraded Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Robert W. Baird lifted their target price on Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Finally, Morgan Stanley set a $288.00 target price on Cencora in a research note on Tuesday, April 15th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $301.18.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.